| |
| |
|
| Insider
Information: |
Zante Greg |
| Relationship: |
Chief Financial Officer |
| City: |
Richmond |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
175,547 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$13,458,876 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
175,547 |
|
|
| Total
Value |
$13,458,876 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 307.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sangamo Biosciences Inc |
SGMO |
VP, Finance & Administ... |
2008-02-14 |
693 |
2004-09-29 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Chief Financial Officer |
2024-05-03 |
174,854 |
2021-01-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-05-03 |
4 |
AS |
$73.49 |
$4,986,008 |
D/D |
(66,756) |
174,854 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-05-03 |
4 |
OE |
$4.68 |
$166,285 |
D/D |
34,249 |
241,610 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-03-27 |
4 |
D |
$83.34 |
$1,384,277 |
D/D |
(16,610) |
207,361 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
223,971 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
D |
$85.22 |
$1,712,325 |
D/D |
(20,093) |
192,304 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
212,397 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
D |
$18.58 |
$257,742 |
D/D |
(13,872) |
195,730 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
S |
$17.90 |
$268,500 |
D/D |
(15,000) |
180,730 |
0 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-01-03 |
4 |
D |
$17.40 |
$854,723 |
D/D |
(49,122) |
209,602 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2024-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
98,334 |
240,491 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-17 |
4 |
AS |
$20.00 |
$150,000 |
D/D |
(7,500) |
149,279 |
0 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-17 |
4 |
OE |
$13.07 |
$98,025 |
D/D |
7,500 |
156,779 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-12 |
4 |
OE |
$5.80 |
$249,026 |
D/D |
41,544 |
190,823 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-12 |
4 |
AS |
$18.00 |
$747,792 |
D/D |
(41,544) |
149,279 |
0 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-11 |
4 |
AS |
$18.00 |
$1,013,518 |
D/D |
(56,295) |
149,279 |
0 |
% |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-04-11 |
4 |
OE |
$4.68 |
$295,778 |
D/D |
56,295 |
205,574 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-01-04 |
4 |
D |
$8.42 |
$174,361 |
D/D |
(20,708) |
185,057 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
90,667 |
229,698 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2023-01-03 |
4 |
D |
$8.52 |
$203,909 |
D/D |
(23,933) |
205,765 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-12-30 |
4 |
D |
$9.40 |
$185,152 |
D/D |
(19,697) |
139,031 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
20,233 |
158,728 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-01-04 |
4 |
D |
$4.62 |
$40,818 |
D/D |
(8,835) |
136,304 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
53,333 |
145,139 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2022-01-03 |
4 |
D |
$4.88 |
$15,113 |
D/D |
(3,097) |
91,806 |
0 |
- |
|
| VKTX |
Viking Therapeutics, Inc. |
Chief Financial Officer |
• – – |
2021-09-28 |
4 |
D |
$6.50 |
$14,989 |
D/D |
(2,306) |
94,485 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
